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Endothelial cell differentiation into capillary-like structures in response to
tumour cell conditioned medium: a modified chemotaxis chamber assay
T Garrido, HH Riese, M Aracil and A Perez-Aranda
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Summary We have developed a modified chemotaxis chamber assay in which bovine aortic endothelial (BAE)
cells degrade Matrigel basement membrane and migrate and form capillary-like structures on type I collagen.
This capillary formation occurs in the presence of conditioned media from highly metastatic tumour cell lines,
such as B16F1O murine melanoma or MDA-MB-231 human breast adenocarcinoma, but not in the presence
of conditioned medium (CM) from the less invasive B16FO cell line. Replacement of tumour cell CM by
1Ong ml-' basic fibroblast growth factor (bFGF) also results in capillary-like structure formation by BAE
cells. An anti-bFGF antibody blocks this effect, showing that bFGF is one of the factors responsible for the
angiogenic response induced by B16FIO CM in our assay. Addition of an anti-laminin antibody reduces
significantly the formation of capillary-like structures, probably by blocking the attachment of BAE cells to
laminin present in Matrigel. The anti-angiogenic compound suramin inhibits in a dose-dependent manner
(complete inhibition with 100 fAM suramin) the migration and differentiation of BAE cells on type I collagen in
response to B16F1O CM. This assay represents a new model system to study tumour-induced angiogenesis in
vitro.
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Angiogenesis is a primary requisite for progression of malig-
nant solid tumours (Folkman, 1992). During tumour growth
and metastasis, endothelial cells proliferate, degrade the sur-
rounding basement membrane and migrate into the stroma.
Finally, they differentiate, giving rise to new vessels (Blood
and Zetter, 1990) which are crucial for nutrient delivery to
tumours.
The interaction of endothelial cells with their microen-
vironment, especially with extracellular matrix components,
plays an essential role during the angiogenic process (Ingber,
1992). It has been shown that basement membrane proteins,
such as laminin (Grant et al., 1989) and type IV collagen
(Ingber and Folkman, 1989) among others, directly induce
the formation of capillary-like structures (CLS) from
endothelial cells. In several ways tumour cells themselves can
also promote angiogenesis, e.g. by secretion of angiogenic
factors, protease activation or macrophage stimulation (Folk-
man and Shing, 1992).
In vivo models, such as the chorioallantoic membrane assay
or the rabbit cornea implant technique, are widely used for
studying angiogenesis. These, however, do not permit evalua-
tion of whether an angiogenic factor or an antiangiogenic
molecule is acting directly on endothelial cells or indirectly
via neighbouring cells, such as inflammatory cells and/or
fibroblasts. Experimental approaches that reproduce the
tumour-induced angiogenic process in vitro will help to study
the molecular mechanisms involved in the interaction
between tumour cells and endothelial cells during angio-
genesis. Since the first description of maintenance of long-
term cultures of capillary endothelial cells by addition of
tumour cell conditioned medium (CM) (Folkman et al.,
1979), several in vitro angiogenesis assays have been des-
cribed (reviewed in Auerbach et al., 1991). These assays, such
as the capillary formation within collagen or gelatin gels
(Montesano and Orci, 1985; Pepper et al., 1992), or the
migration ofendothelial cells in the silicon template compart-
mentalisation technique (Augustin-Voss and Pauli, 1992),
permit the analysis of the effect of angiogenic factors or
tumour cell CM on individual angiogenic steps.
We have developed a modified chemotaxis chamber assay
that allows simultaneous study of the different steps of the
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overall angiogenic process: in this assay endothelial cells
stimulated by tumour cell CM degrade basement membrane
Matrigel, migrate towards the angiogenic stimulus and form
CLS on type I collagen. This assay represents a useful tool
for the study of factors involved in tumour-induced
angiogenesis and for the characterisation ofspecific inhibitors
of this process.
Materials and methods
Cell lines and culture conditions
Bovine aortic endothelial (BAE) cells and the B16F1O murine
melanoma cell line were obtained from Farmitalia Carlo
Erba (Nerviano, Italy). B16FO murine melanoma and MDA-
MB-231 human breast carcinoma cell lines were obtained
from the American Type Culture Collection (Rockville, MD,
USA). Cell lines were cultured at 37°C, in a 5% carbon
dioxide atmosphere, in Dulbecco's modified Eagle medium
(DMEM) (Gibco, UK) (BAE cells, B16FO and MDA-MB-
231) or RPMI-1640 (Flow, UK) (Bl6F1O), supplemented
with 10% fetal calf serum (FCS) (Seralab, UK), 2 mM
glutamine (Seralab, UK), 100 IUmli penicillin and 0.1mg
ml-' streptomycin. Cell lines were routinely checked by the
Gen-Probe rapid detection system (Gen-Probe, San Diego,
CA, USA) for mycoplasma contamination.
Reagents
Basement membrane Matrigel and type I collagen were pur-
chased from Collaborative Biomedical Products (Bedford,
MA, USA). Human recombinant basic fibroblast growth
factor (bFGF) was obtained from Farmitalia Carlo Erba.
Suramin was purchased from Bayer (Leverkusen, Germany).
Anti-mouse laminin and anti-human bFGF antibodies were
obtained from Collaborative Biomedical Products.
Production oftumour cell CM
Approximately 4 x 106 B16FO, B16FIO or MDA-MB-231
tumour cells were grown to subconfluency in culture medium.
After washing three times with phosphate-buffered saline
(PBS), serum-free medium was added. Three days later CM
was harvested, centrifuged for 5 min at 500g, passed throughTumour-induced angiogenesis model
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a 0.22 tm pore size filter and stored at - 20°C until use. As
the growth rate of cell lines was different, conditioned media
were conveniently diluted to a similar number of cells per
volume at the time of harvesting in order to reduce the








Figure 1 (a) Scheme of a Transwell cell culture chamber used in
the tumour-induced angiogenesis assay. Each well contains a
Transwell insert (I) with a polycarbonate membrane (M); the
insert delimits an upper chamber (U) and a lower chamber (L).
(b) Magnification of the separation between both chambers: A,
BAE cells in the upper chamber; B, Matrigel coating the upper
side of the filter; C-, 8 jAm pore polycarbonate filter; D, type I
collagen coating the bottom side of the filter (in some
experiments type I collagen was replaced by Matrigel); E, tumour
cell CM in the lower chamber (in some experiments CM was
replaced by bFGF).
In vitro tumour-induced angiogenesis assay
Polyvinylpyrrolidone-free polycarbonate filter Transwell in-
serts (6.5 mm diameter) with 8 tLm pores (Costar, Cambridge,
MA, USA) were used for the assay. Matrigel (50iLl from a
250jgml1 dilution in cold PBS) was applied to the upper
surface of each filter and dried at room temperature under a
hood. The underside of the filter was then coated with type I
collagen (50 Ll from a 250 Lg ml-' dilution in 0.02M acetic
acid); in some experiments Matrigel (50gl from a 750jig
ml-' dilution in cold PBS) was used instead of type I col-
lagen. Tumour cell CM (6001lI) was added to the lower
chamber. Approximately 105 BAE cells (100 gl) were seeded
in the upper chamber in DMEM supplemented with 0.2%
bovine serum albumin. After incubation for 72 h at 37°C in a
5% carbon dioxide atmosphere, cells on the upper side ofthe
filter were removed with cotton swabs. Filters were then
stained with haematoxylin-eosin or with a Giemsa-modified
staining method. The formation of CLS was assessed under
the microscope and compared with controls having non-
conditioned culture medium in the lower chamber.
Results
Tumour cell-inducedformation ofCLS in BAE cells
In order to study whether tumour cell CM could induce the
formation of CLS in BAE cells, these were added to the
upper compartment of Transwell cell culture chambers, and
CM from either B16FO or B16F1O cells, murine melanoma
cells with different metastatic capacity (Fidler, 1973), was
Figure 2 Formation of CLS by BAE cells in the tumour-induced angiogenesis assay. BAE cells were seeded in the upper chamber
and after 3 days incubation the development of CLS on the bottom of the filter was evaluated. BAE cells formed CLS on type I
collagen in response to B16 FI0 CM (a), but not to BI6FO CM (b). When the type I collagen coating of the bottom side of the
filter was replaced by Matrigel, BAE cells formed CLS also in the presence of B16FO CM (c). BAE cells also formed CLS on type I
collagen when tumour cell CM was replaced by 10 ng ml- ' bFGF (d). Giemsa staining of the bottom side of the Transwell inserts
is shown in all photomicrographs; filter pores appear as white circles. Original magnifications x 100; inserts in a and b, x 10.
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added to the lower chamber; the filters of the Transwell
inserts had been previously coated with Matrigel on the
upper side and with type I collagen on the lower side (Figure
1). The amount of Matrigel (12.5fig) was sufficient to create
a basement membrane-like barrier but was unable to induce
the formation of CLS by BAE cells (data not shown). When
CM from the highly metastatic B16F1O cell line was present
in the lower well, within 72 h BAE cells degraded Matrigel,
migrated through the filter pores and differentiated into CLS
on the type I collagen coating (Figure 2a). This CLS forma-
tion could also be observed using CM from the human
metastatic breast adenocarcinoma cell line MDA-MB-231
(data not shown). In contrast, when CM of the less invasive
Bl6FO cell line was used, no CLS were fonned on type I
collagen (Figure 2b). However, when the lower coating of the
filters contained Matrigel (37.5gig) instead of type I collagen,
no differences were observed between B16FlO (data not
shown) and B16FO CM (Figure 2c) and CLS were formed in
both cases. Formation of CLS on type I collagen or Matrigel
required in any case the presence of tumour cell CM, since
few BAE cells migrated through the Matrigel layer and no
differentiation was observed when non-conditioned culture
medium was added to the lower compartment of the chamber
(data not shown).
Figure 3 Effect of an anti-bFGF antibody (a), an anti-laminin antibody (b and c) and suramin (d-f) on the formation of CLS on
type I collagen by BAE cells in response to B16F1O CM. CLS formation was studied using the tumour-induced angiogenesis assay.
Formation of CLS was abolished when an anti-bFGF antibody was added to the lower chamber (a). An anti-laminin antibody
partially inhibited the formation of CLS when added to the upper chamber (b), but it had no effect when added to the lower
chamber (c). When 1OiM (d) or 100#AM suramin (e) was added to the lower chamber a dose-dependent inhibition of CLS
formation by BAE cells was observed; however, this inhibition was not observed when 100 tM suramin was added to the upper
chamber (f). Giemsa staining of the bottom side of the Transwell inserts is shown in all photomicrographs. Original magnifications
x 100.Tumourinduced anglogenesis model
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Table I Formation of CLS in response to tumour cell CM. Summary of the results
Bottom side coating
Chemoattractant ofthefilter Additionsa CLSformationb Figurec
B16F10 CM Type I collagen - + 2a
B16FIO CM Matrigel - + NS
MDA-MB-231 CM Matrigel - + NS
B16FO CM Type I collagen - - 2b
B16FO CM Matrigel - + 2c
None Type I collagen - - NS
bFGF (10 ng ml) Type I collagen - + 2d
B16F1O CM Type I collagen Anti-bFGF (L) - 3a
B16FIO CM Type I collagen Anti-laminin (U) + 3b
B16FIO CM Type I collagen Anti-laminin (L) + 3c
B16F1O CM Type I collagen I0O4M suramin (L) + 3d
B16FIO CM Type I collagen 100!lM suramin (L) - 3e
B16FIO CM Type I collagen IOgM suramin (U) + NS
B16F1O CM Type I collagen 100jAM suramin (U) + 3f
aL, lower chamber; U, upper chamber. b±, partial inhibition. CNS, results not shown.
bFGF-inducedformation ofCLS
To evaluate whether bFGF, one of the most potent
angiogenic factors known, is responsible for the angiogenic
effect exerted by B16F10 CM, a neutralising anti-bFGF
antibody (100 sgml-') was added together with the tumour
cell CM; in this case the formation of CLS was abolished
(Figure 3a). Moreover, capillary formation was induced on
type I collagen when B16F10 CM was replaced by
10ngml-l bFGF (Figure 2d).
Laminin-inducedformation ofCLS
Laminin is one of the major constituents of Matrigel. To
evaluate the role of this basement membrane protein in our
in vitro tumour-induced angiogenesis model, in a separate set
of experiments an anti-laminin antibody (100ilgml-') was
added to the upper chamber, thus coming into contact with
the Matrigel coating the filter. A reduction in the formation
of CLS on type I collagen was observed (Figure 3b) when
compared to conditions without antibody (Figure 2a).
Moreover, addition of the anti-laminin antibody to the lower
chamber, and thus in contact with the type I collagen coating
the underside of the filter, had no effect on the formation of
CLS by BAE cells (Figure 3c).
Inhibition oftheformation ofCLS by suramin
The effect of the anti-angiogenic and anti-tumorigenic agent
suramin was evaluated in our model system. Addition of
non-toxic concentrations of suramin (10 and 1OO1M) to the
lower chamber throughout the incubation period resulted in
a marked dose-dependent effect, preventing endothelial cells
from migrating and differentiating on type I collagen in
response to B16F10 CM (Figure 3d and e). This inhibitory
effect was not noticeable when suramin was added to the
upper compartment of the Transwell cell culture chambers
(Figure 3f).
A summary of the results is shown in Table I.
Discussion
Long-term cultures of capillary endothelial cells were firstly
obtained by co-culture with tumour cell CM, thereby sugges-
ting that tumour cells produce growth factors necessary for
endothelial cell proliferation (Folkman et al., 1979). Later,
taking advantage of this fact, in vitro assays specific for single
steps of the angiogenic process (migration, invasion, differen-
tiation, proliferation of endothelial cells) were developed and
were applied to study the regulatory mechanisms of
angiogenesis and to screen for inhibitors (Auerbach et al.,
1991). Differentiation of mouse lung endothelial cells cul-
tured on plastic has been achieved in the presence of Lewis
lung carcinoma CM (Li et al., 1991). Changes in DNA and
RNA content and synthesis were also observed when BAE
cells were placed in contact with CM from human astro-
cytoma cells (Silbergeld et al., 1992). Thompson et al. (1991)
observed the induction of endothelial cell chemotaxis and
invasion through type IV collagen and Matrigel-coated
filters, respectively, by adding AIDS-related Kaposi's sar-
coma cell CM to the lower well of a Boyden chamber. A
similar assay for endothelial cell invasion has been described
by Murata et al. (1991) based on the use of Transwell
chambers; in their system invasion through Matrigel is
induced by B16B26 murine melanoma CM as chemoattrac-
tant.
On the other hand, systems that use co-cultures instead of
tumour cell CM have demonstrated that cell-to-cell contacts
between tumour and endothelial cells can also contribute to
the formation of new vessels. Co-cultures of astroglial cells
with bovine retinal endothelial cells result in the formation of
capillary structures (Laterra and Goldstein, 1991). A model
system for tumour angiogenesis, based on the co-culture of
tumour cell lines with endothelial cells in Transwell cell
culture chambers, has recently been described. Using this
co-culture system, tubular morphogenesis by human omen-
tum microvascular endothelial cells in type I collagen gels
was shown to be induced by transforming growth factor
alpha (TGF-x)-producing oesophageal tumour cells (Oka-
mura et al., 1992) or keratinocytes (Ono et al., 1992). BAE
cells also form capillary structures in type I collagen when
co-cultured with human glioma cell lines (Abe et al., 1993);
in this case a direct correlation between tubulogenesis of
BAE cells and bFGF mRNA levels in glioma cells was
demonstrated. These findings support the hypothesis that
tumour cells directly control not only the proliferation and
invasion steps, but also the differentiation of endothelial cells
during tumour-induced angiogenesis.
In order to develop a system able to reproduce simul-
taneously the overall angiogenic process, i.e. tumour-induced
endothelial cell invasion and differentiation, we modified the
chemotaxis chamber assay (Albini et al., 1987) in such a way
that tumour cell CM induces the degradation of a Matrigel
barrier by endothelial cells, their migration through it and
their subsequent differentiation into CLS on a type I collagen
layer. Although our tumour-induced angiogenesis assay
shows homology to the co-culture system described by Abe et
al. (1993), there is a substantial difference between the
models. In Abe's model, BAE cells seeded on a type I
collagen gel migrate into it and differentiate into capillary
structures; this tubulogenesis inside the gel requires a pro-
teolytic degradation of type I collagen involving the activa-
tion of latent collagenase by tissue-type plasminogen
activator (Sato et al., 1993). In our model system, type I
collagen degradation takes place at the lower site ofthe filter,
but an additional invasion step needs to take place in the
Matrigel coating the upper side of the Transwell inserts. ThisTumour-induced angiogenesismodel
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Matrigel coating mimics more closely the in vivo situation in
which endothelial cells have to degrade the basement mem-
brane, whereas the type I collagen coating of the underside of
the filter creates an environment similar to the interstitial
matrix of the surrounding connective tissue, appropriate for
the endothelial cells to organise into capillary structures. In
summary, in our tumour-induced angiogenesis model, forma-
tion of CLS by BAE cells requires not only the activation of
latent collagenases, but also the activation of type IV col-
lagenases and other matrix metalloproteinases required for
the degradation of Matrigel constituents.
In our model system BAE cells formed CLS on type I
collagen in the presence of CM from the highly metastatic
melanoma cell line B16FIO (Figure 2a), but CLS formation
did not take place when CM from the less invasive B16FO
cell line was used (Figure 2b). It is possible that B16FO cells
do not produce sufficient amounts of angiogenic factors to
induce the migration and differentiation of BAE cells, in
contrast to B16F1O cells. Nevertheless, the possibility that
B16FO cells produce TGF-P or other factors antagonising the
effects of bFGF cannot be ruled out.
Formation of CLS could be blocked by anti-bFGF
antibodies (Figure 3a), suggesting a role for this angiogenic
factor in the tumour-dependent induction of angiogenesis
shown in our assay, although other factors can be involved
as well. The lack of signal sequences in the bFGF gene
argues against its secretion via classical mechanisms; how-
ever, its externalisation and release into the culture medium
by novel mechanisms has been proposed (Mignatti and Rif-
kin, 1991). The blocking of the effects of Bl6F0 CM by
anti-bFGF antibody in our assay could therefore be
explained if bFGF was released by such yet undefined
mechanisms. A similar effect of anti-bFGF antibodies on the
conditioned media of glioma cell lines has been described
(Abe et al., 1993).
When Matrigel is used instead of type I collagen for
coating the lower side of the filters, CLS formation is
induced even in the presence of B16FO CM (Figure 2c),
suggesting that a Matrigel constituent (probably bFGF) is
triggering the migration and differentiation of BAE cells;
nevertheless, the presence of a chemoattractant factor (either
bFGF or others) in the tumour cell CM in the lower
chamber is an essential requirement for our assay since
neither migration nor differentiation of BAE cells occurs
when non-conditioned culture medium is used.
Laminin and other basement membrane components have
been described as modulators of angiogenesis in vitro (Grant
et al., 1989; Ingber and Folkman, 1989). In our tumour-
induced angiogenesis model anti-laminin antibodies did not
completely block the formation of CLS but reduced their
number significantly (Figure 3b). This is probably due to an
inhibition of the attachment of BAE cells to laminin and the
subsequent laminin-induced secretion of matrix metallo-
proteases (Turpeenniemi-Hujanen et al., 1986), thereby
blocking the migration and invasion of BAE cells through
the Matrigel layer. The incomplete inhibition of CLS forma-
tion by anti-laminin antibodies in our assay could mean that
other Matrigel components (probably type IV collagen,
among others) are also involved in these events.
In order to validate this assay as a tool for studying
tumour-induced angiogenesis, and especially for testing
inhibitors, we evaluated the effect of suramin as a potential
inhibitor. The mechanism of the anti-angiogenic activity of
suramin is not completely understood, but the interaction of
suramin with heparin-binding growth factors, such as bFGF,
has been reported (Stein, 1989), as well as the in vitro inhibi-
tion of the binding of several growth factors (such as bFGF,
EGF, insulin-like growth factor I and platelet-derived growth
factor) to their cell-surface receptors on endothelial cells.
Moreover, suramin has been recenlty reported to inhibit each
of the key control points of angiogenesis: endothelial cell
migration, proliferation and production of proteases (Takano
et al., 1994). In our in vitro model, suramin, when added to the
lower chamber, inhibited in a dose-dependent manner CLS
formation by BAE cells on type I collagen (Figure 3d and e);
this is probably due to binding to bFGF present in B16F1O
CM, thereby neutralising its biological activity. This inhibition
of tubular morphogenesis by suramin was much lower when
the drug was added to the upper compartment (Figure 3f) than
when it was added to the lower compartment of the Transwell
cell culture chamber. This differential effect of suramin
could be the result of its binding to heparan sulphate pro-
teoglycans, one of the major components of Matrigel, there-
by sequestering the drug and reducing its effective concentra-
tion; in this way, the ability of suramin to interact with
growth factor receptors on endothelial cells and to diffuse
through the filter, blocking bFGF in the lower chamber,
would be greatly reduced.
In conclusion, in this in vitro model system we are able to
study in combination the different steps that could be
assayed separately with other previously described in vitro
angiogenesis assays, i.e. basement membrane degradation
(Murata et al., 1991), endothelial cell migration towards
angiogenic factors (Augustin-Voss et al., 1992) or capillary
formation within three-dimensional collagen gels (Pepper et
al., 1992; Abe et al., 1993). This system reflects more closely
the in vivo situation, and therefore we think that our tumour-
induced angiogenesis model represents a valuable tool for the
study of molecular interactions during the angiogenic pro-
cess.
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